Atebimetinib

N/A

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameAtebimetinib
Drug Alias NameIMM-1-104
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase
Therapy Area/IndicationsSkin MelanomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmuneering Corp
China Registration ClassN/A

Develop Information

Active CompaniesImmuneering Corp
Inactive CompaniesN/A
Active IndicationsSkin MelanomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A